Human trial
Selank: active-comparator anxiety study (2008)
62 patients with generalized anxiety disorder or neurasthenia; 30 Selank and 32 medazepam.
Reported findings. Authors reported similar anxiety improvement to medazepam and antiasthenic effects.
Nonresponse. Nonresponse frequency not established in this excerpt.
Harms. Unknown in reviewed excerpt; absence of mention is not safety evidence.
Limits. Small historical active-comparator study without placebo; blinding and long-term safety detail are limited. Findings do not transfer to N-acetyl/amidated analogues.
Preparation: Source preparation; commercial equivalence unverified. Route: Unknown in reviewed excerpt; do not infer.
Read original source ↗Editorial review 2026-10-09. Clinician review pending.